Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Regeneron Pharmaceuticals
(NQ:
REGN
)
891.37
-15.17 (-1.67%)
Streaming Delayed Price
Updated: 12:25 PM EDT, Apr 25, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Regeneron Pharmaceuticals
< Previous
1
2
3
4
5
Next >
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) is a Leading Gainer in 5/19 Morning Trading
May 19, 2023
Via
Investor Brand Network
Regeneron Announces Investor Conference Presentations
May 18, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Regeneron Applauds Supreme Court’s Unanimous Opinion Striking Down Amgen’s PCSK9 Patent Claims and Supporting Scientific Innovation
May 18, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Regeneron Beats Q1 Views, But Stock Drops On Weak Eye Med Sales
May 05, 2023
Regeneron reported better-than-expected Q1 earnings and revenue, but its Eylea sales fell, losing ground to Roche's newly launched Vabysmo.
Via
MarketBeat
Regeneron Pharmaceuticals (NASDAQ: REGN) is a Leading Gainer in 3/23 Morning Trading
March 23, 2023
Via
Investor Brand Network
Regeneron Reports First Quarter 2023 Financial and Operating Results
May 04, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Regeneron to Highlight New and Updated Clinical Data at ASCO Showcasing Breadth of Cancer Research
May 02, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Alnylam and Regeneron Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
April 26, 2023
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Regeneron and Alnylam Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
April 26, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Regeneron Announces Retirement of Board Chair, Dr. P. Roy Vagelos, Accomplished Physician-Businessman and Industry Luminary
April 17, 2023
Dr. Leonard S. Schleifer and Dr. George D. Yancopoulos to become Co-Chairs of the Board and Christine A. Poon to be named Lead Independent Director
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Aflibercept 8 mg and EYLEA® (aflibercept) Injection Presentations at ARVO Provide New Insights into the Treatment of Serious Retinal Diseases
April 17, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Regeneron Announces Investor Conference Presentations
April 11, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Regeneron to Report First Quarter 2023 Financial and Operating Results and Host Conference Call and Webcast on May 4, 2023
April 03, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Libtayo® (cemiplimab) in Combination with Chemotherapy Approved by European Commission for the First-line Treatment of Advanced PD-L1 Positive Non-small Cell Lung Cancer (NSCLC)
March 29, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Sonoma Biotherapeutics and Regeneron Announce Collaboration to Discover, Develop and Commercialize Treg Cell Therapies for Autoimmune Diseases
March 28, 2023
From
Sonoma Biotherapeutics, Inc.
Via
Business Wire
Regeneron and Sonoma Biotherapeutics Announce Collaboration to Discover, Develop and Commercialize Treg Cell Therapies for Autoimmune Diseases
March 28, 2023
Sonoma Biotherapeutics to receive $75 million upfront, inclusive of $45 million cash and $30 million equity investment; potential for an additional $45 million development milestone payment
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
March 27, 2023
Sanofi and Regeneron bolted higher on news about their jointly developed COPD medication Dupixent. Analysts say sales may hit $20 billion within a decade.
Via
MarketBeat
Dupixent® (dupilumab) Demonstrates Potential to Become First Biologic to Treat COPD by Showing Significant Reduction in Exacerbations in Pivotal Trial
March 23, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
FDA Approves First-in-class Evkeeza® (evinacumab-dgnb) for Young Children with Ultra-rare Form of High Cholesterol
March 22, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Dupixent® (dupilumab) Approved by European Commission as First and Only Targeted Medicine for Children as Young as Six Months Old with Severe Atopic Dermatitis
March 21, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Dupixent® (dupilumab) Late-Breaking Data at AAD Show Significant Improvements in Signs and Symptoms of Moderate-to-severe Atopic Hand and Foot Dermatitis
March 18, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Students Win More Than $1.8 Million at 2023 Regeneron Science Talent Search for Remarkable Scientific Research on RNA Molecule Structure, Media Bias, and Diagnostics for Pediatric Heart Disease
March 14, 2023
$250,000 top award goes to Neel Moudgal in the nation’s oldest and most prestigious science and math competition for high school seniors
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Dupixent® (dupilumab) Application for Treatment of Chronic Spontaneous Urticaria (CSU) in Adults and Adolescents Aged 12 Years and Older Accepted for FDA Review
March 07, 2023
More than 300,000 people in the U.S. suffer from CSU that is inadequately controlled by antihistamines
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Kevzara® (sarilumab) Approved by FDA as First and Only Biologic Indicated for Patients with Polymyalgia Rheumatica
February 28, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Libtayo® (cemiplimab) in Combination with Chemotherapy Receives Positive CHMP Opinion for the Treatment of Advanced PD-L1 Positive Non-small Cell Lung Cancer (NSCLC)
February 24, 2023
Recommendation based on a Phase 3 trial demonstrating superior survival outcomes for Libtayo plus chemotherapy compared to chemotherapy alone
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Aflibercept 8 mg BLA for Treatment of Wet Age-Related Macular Degeneration and Diabetic Macular Edema Accepted for FDA Priority Review
February 23, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Analyst Confidence in Eli Lilly Boosted by Product Pipeline
February 22, 2023
Eli Lilly has long been a reliable stock, but with the company's impressive product pipeline, the stock could hold significant potential in the near term.
Via
MarketBeat
3 More Mid-Cap Biotechs The Street Sees Doubling
February 22, 2023
According to Wall Street research groups, these three mid-cap biotechs have 2x potential. It’s for the investor to decide if the upside justifies the risk.
Via
MarketBeat
Pozelimab (C5 Antibody) BLA for Treatment of Children and Adults with Ultra-rare CHAPLE Disease Accepted for FDA Priority Review
February 21, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
EYLEA® (aflibercept) Injection Approved as the First Pharmacologic Treatment for Preterm Infants with Retinopathy of Prematurity (ROP) by the FDA
February 08, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.